Study details
Enrolling now
Ublituximab (Briumvi) Trial
Northwestern University
NCT IDNCT07225361ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
40
Study length
about 3.7 years
Ages
18–70
Locations
1 site in IL
About this study
This trial is testing a treatment called Ublituximab in people with early forms of relapsing multiple sclerosis. The goal is to see if this treatment is safe and tolerable, as well as how it affects plasma neurofilament light chain levels over time.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ublituximab
PhasePhase 4
DrugUblituximab
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
ublituximab
Body systems
Neurology